Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q4 FY2021 Earnings Presentation
56 slides from Morepen Laboratories's earnings presentation, May 4, 2021
Slide 1: Exchange filing cover letter
Date: 04/05/2021 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investors Presentation (Q4’FY21) May, 2021 Dea
Slide 2: Morepen Laboratories Q4'FY21 Investor Presentation
MOREPEN LABORATORIES LIMTED Q4'FY21 Investor Presentation May 2021
Slide 3: Disclaimer/ Confidentiality
Disclaimer/ Confidentiality This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied
Slide 4: Annual Highlights
CONSOLIDATED Rs. in crores 12M'FY21 ANNUAL HIGHLIGHTS ^39% ^67% Net Revenue 862.55 1200.12 EBIDTA 78.00 130.58 ^189% Profit after Tax ^152% ^189% Profit before Tax EPS (12M) 33.58 97.09 FY20 FY21 39.10 98.51 Rs. 0.75 Rs. 2.16 FY20 FY21 FY20 FY21
Slide 5: Quarterly Highlights
CONSOLIDATED Rs. in crores Q4'FY21 QUARTERLY HIGHLIGHTS ^40% ^68% Net Revenue 208.39 290.76 EBIDTA 20.61 34.56 ^143% Profit after Tax ^143% ^136% Profit before Tax EPS (3M) 11.02 26.76 Q4'FY20 Q4'FY21 11.36 27.63 Rs. 0.25 Rs. 0.59 Q4'FY20 Q4'FY21 Q4'FY20 Q4'FY21
Slide 6: Fresh Equity Infusion
equity update MAY'21 FRESH EQUITY INFUSION $32.50 MILLION corinth group switzerland Promoters increasing stake from 9.41% EQUITY STAKE 34.54% to 44.28% Approved by the board on 28.4.21" 70 million warrants in FY21 25% - subscription received 75% - to be received within 18 months pre-issue holdings p
Slide 7: Consolidated annual operational performance
CONSOLIDATED annual operational performance
Slide 8: Revenue Growth
CONSOLIDATED Rs. in crores 12M'FY21 REVENUE GROWTH 1,250 ^39% ^40% 1200 1,000 863 300 750 290.76 772 200 610 208.38 500 100 250 0 FY20 FY21 0 FY'18 FY'19 FY'20 FY'21 Quarterly performance 25% CAGR
Slide 9: Export Revenue
CONSOLIDATED (Company-wide) Rs. in crores 12M'FY21 EXPORT REVENUE 500 ^39% 477 400 ^34% 343 300 200 312 150 ^48% 171.70 200 236 100 119.06 100 50 40% exports FY21 0 0 Export Domestic FY'18 FY'19 FY'20 FY'21 Q4'FY21 revenue split 26% CAGR
Slide 10: API Business, Medical Devices, Formulations, OTC
API BUSINESS MEDICAL DEVICES FORMULATIONS OTC (SUBSIDIARY)
Slide 11: Segment Wise Growth
consolidated Rs. in crores 12M'FY21 SEGMENT WISE GROWTH 750 ^44% ^71% 300 150 -5% 100 ^32% 682.99 287.37 137.56 131.36 75 500 200 100 85.55 473.95 168.35 50 64.73 250 100 50 25 0 0 FY20 FY21 FY20 FY21 0 0 FY20 FY21 FY20 FY21 API DIAGNOSTICS FORMULATIONS DR.MOREPEN -OTC
Slide 12: Segment Wise Breakup
standalone Rs. in crores 12M'FY21 SEGMENT WISE BREAKUP FY'20 FY'21 Formulations 11.9% API 1.20% 60.8% 62.0% Diagnostic Devices 26.1% Diagnostics 4.50% 21.6% 26.1% API 62% formulations 5.70% 17.6% 11.9% revenue split FY'21
Slide 13: API Business
API BUSINESS leadership through quality
Slide 14: API Revenue
api business Rs. in crores 12M'FY21 API REVENUE 750 ^44% ^51% 683 500 474 200 413 171.29 150 339 250 100 113.20 50 0 0 Q4'FY20 Q4'FY21 FY'18 FY'19 FY'20 FY'21 Quarterly performance 26% CAGR
Slide 15: API Export
api business Rs. in crores 12M'FY21 API EXPORT 500 ^39% 473 400 125 ^48% 300 309 341 117.88 100 ^59% 200 235 75 50 53.41 100 25 69% exports FY21 0 0 Export Domestic FY'18 FY'19 FY'20 FY'21 Q4'FY21 revenue split 26% CAGR
Slide 16: Global Customers
api business Rs. in crores 12M'FY21 GLOBAL CUSTOMERS Africa 7.9% S. America ^14% 1,000 11.3% 826 USA 750 Asia 723 1.5% 40.7% 589 500 Europe 826 customers 451 11.1% 250 0 103 new customers FY'18 FY'19 FY'20 FY'21 added in FY21 India increasing customer base 27.6%
Slide 17: Continent Wise Growth
Rs. in crores api business 12M'FY21 CONTINENT WISE GROWTH 826 customers ^36% ^21% ^48% ^55% ^70% ^47% 75 125 300 250 40 20 200 18.92 68.22 100 107.94 251.55 202.51 30 15 50 200 31.57 50.28 75 89.25 150 12.87 170.29 20 10 50 100 131.06 18.59 25 100 50 10 5 25 0 0 0 0 0 0 FY20 FY21 FY20 FY21 FY20 FY21
Slide 18: Continent Wise Growth
api business Rs. in crores 12M'FY21 CONTINENT WISE GROWTH Others 24.4% India 750 29.7% 680.71 S. Africa S. America USA 500 472.35 Europe 411.85 Israel TOP 10 340.32 2.6% Pakistan countries India 2.7% Thailand 250 2.7% Germany USA 3.6% Asia 10% Iran 5.2% 0 FY'18 FY'19 FY'20 FY'21 China B'desh 5.7% Sp
Slide 19: R&D Centre
api business R&D CENTRE t h e b a c k b o n e o f A P I
Slide 20: R&D Core Competence
api business R&D CORE COMPETENCE NON-INFRINGING NEW POLYMORPHS process & patents development COST EFFECTIVE IMPURITY processes profiling
Slide 21: Specialised Chemistry Skills
api business SPECIALISED CHEMISTRY SKILLS GRIGNARD FRIEDEL-CRAFT STEREOSELECTIVE reaction reaction chiral reduction CYNATION HECK SN2 reaction reaction reaction one of few select indian companies carrying out highly sensitive and complex reactions at plant level since last 25 years at 3KL to 5KL rea
Slide 22: Intellectual Property
api business INTELLECTUAL PROPERTY USA Europe Japan 135 129 patents DMFs korea China Taiwan Australia 13 30 china idls new products FY'21: 10 patent, 18 dmf, 1 IDL, 5 new products
Slide 23: API Expansion
API EXPANSION CAPITALISING BIG OPPORTUNITY
Slide 24: APIs Going Off Patent
api business APIS GOING OFF PATENT 50 USD billion 15 blockbuster drugs going off patent in next 5 years 40 42.07 morepen ready with generic version to launch at patent expiry 30 $42 BILLION 20 18.84 20.29 market size in 2025 16.00 10 9.70 15X morepen market to grow 15 times from 0 2021 2022 2023 202
Slide 25: API Expansion at Baddi
api business API EXPANSION AT BADDI 178 CR 3 YEARS 700 project cost completion time new hirings 2000 MT 40 4217 CR installed capacity new products production value project approved by state govt, environment clearance obtained
Slide 26: Medical Devices
MEDICAL DEVICES market leadership
Slide 27: Medical Devices Revenue Growth
medical devices Rs. in crores 12M'FY21 REVENUE GROWTH 300 ^71% ^57% 287.35 75 200 62.86 168.35 50 139.75 100 39.93 103.35 25 0 Q4'FY20 Q4'FY21 0 FY'18 FY'19 FY'20 FY'21 Quarterly performance 41% CAGR
Slide 28: Growth Drivers
medical devices GROWTH DRIVERS ^51% 117% gluco meters BP Monitors
Slide 29: Gluco Meters
medical devices GLUCO METERS 5 MILLION 600 MILLION meters installed strips sold so far Fy21 1.69 MILLION Fy21 188 MILLION
Slide 30: Devices Expansion
DEVICES EXPANSION leadership in POC devices
Slide 31: Devices R&D Centre
medical devices DEVICES R&D CENTRE scaling up R&D Team to create world class R&D Centre for medical devices in india CORE KEY BACKWARD technologies hi-tech components integration CONNECTED DATA QUICK devices mining using AI and ML rapid tests
Slide 32: Devices Expansion Plan
medical devices DEVICES EXPANSION PLAN immediate requirements and focus the new products are proudly developed by in house R&D team OXIMETERS OXYGEN PATIENT and related devices concentrators monitors FERTILITY RAPID TESTS PAIN pregnancy & ovulation for infectious diseases managment devices
Slide 33: Three Year Vision
medical devices THREE YEAR VISION backward integration into core technologies ENZYMES PCB/SMT MOLECULAR for In-vitro devices lines for all devices sieves & filters ACQUISITIONS JV PARTNERS CONNECTED similar products for technologies devices & data
Slide 34: Devices Expansion Plan
medical devices DEVICES EXPANSION PLAN 150 CR 2 YEARS 500 project cost completion time new hirings ROBOTIC 10 2000 CR controls new products production value At adjoining site at baddi only, land owned by the promoters
Slide 35: Formulations
FORMULATIONS branded & generic formulations
Slide 36: Formulations Gross Revenue
formulations Rs. in crores 12M'FY21 GROSS REVENUE 200 40.o 30.o -13% 33.08 150 100 110.51 153.17 137.57 -5% 130.73 28.21 20.o 50 10.o 0.o Q4'FY20 Q4'FY21 0 FY'18 FY'19 FY'20 FY'21 Quarterly performance
Slide 37: Expansion: ANDAs for regulated markets
formulations EXPANSION andas for regulated markets
Slide 38: R&D & Product Development
formulations R&D & PRODUCT DEVP. setting up formulation development centre at par with international standards NON- INFRINGING NOVEL NOVEL processes formulations polymorphic forms NDDS SUSTAINED NEW with least drug substance release tablets combination
Slide 39: ANDAs for USA Markets
formulations ANDAS FOR USA MARKETS working on 13 andas with 41 different strengths DIABETES CARDIAC OTHERS 6 products-14 strengths 5 products-24 strengths 2 products-3 strengths $6.25 BN $23.61 BN $ 0.76 BN market size at expiry market size at expiry market size
Slide 40: ANDAs for USA Markets
formulations ANDAS FOR USA MARKETS development lab scale bench scale completed completed development 6 PRODUCTS 2 PRODUCTS 5 PRODUCTS ready with 6m stability prototype FRML available bench scale PILOT BIO TECH-TRANSFER TECH PACK within 3 months within 3 months within 6 months
Slide 41: World Class ANDA Project
formulation WORLD CLASS ANDA PROJECT 100 CR 2 YEARS 300 project cost completion time new hirings AUTOMATIC 25 2000 CR filling & packing lines new products production value At existing site at baddi only, land parcel already ear marked
Slide 42: OTC, Health & Nutrition
Dr. Morepen® OTC, HEALTH & NUTRITION
Slide 43: OTC Gross Revenue
Rs. in crores 12M'FY21 GROSS REVENUE ^32% 100 ^26% 85.55 75 25 64.63 20 22.43 50 54.38 48.89 15 17.78 10 25 5 0 Q4'FY20 Q4'FY21 0 FY'18 FY'19 FY'20 FY'21 Quarterly performance 20% CAGR
Slide 44: Health & Nutrition
HEALTH & NUTRITION 54% 3% health & nutrition online sales skin collagen muscle food sexuall wellness green tea & honey immunity disinfectants sanitizers omega-3 stress & sleep slim shake general health new launches in FY21 exclusive online range launched at dr.morepen.com
Slide 45: Personal Grooming
PERSONAL GROOMING 26% 26% online sales
Slide 46: Speciality Skincare
SPECIALITY SKINCARE DEEP CLEANSER VITAMIN-C SERUM see you soon PROBIOTIC BODY SCRUB
Slide 47: Expansion
EXPANSION expanding the product basket & reach
Slide 48: R&D & Product Development
R&D & PRODUCT DEVP. investing heavily on product development in various areas HEALTH NUTRACEUTICALS ENERGY & fitness products products drinks & capsules AYURVEDA HIGH-END PACKAGING with a scientific backing cosmetology innovations
Slide 49: Expansion Plan
EXPANSION PLAN capitalising on the Equity of Dr.Morepen - a household brand OTC- TRADE ONLINE GROOMING 100 products health & Nutrition 200 products available 500 1000 500 products in three years products in three years products in three years
Slide 50: Dr. Morepen Expansion
DR. MOREPEN EXPANSION 100 CR 2 YEARS ONLINE project cost completion time full ecommerce set up BRAND SOCIAL 1000 CR building & surveys media & reach sales value
Slide 51: Financial highlights & ratios
consolidated FINANCIAL highlights & ratios
Slide 52: Financial Highlights (Quarterly)
consolidated Rs. in crores Q4'FY21 FINANCIAL HIGHLIGHTS ^40% ^36% ^68% ^143% ^143% ^143% 300 300 40 30 30 0.6 290.76 30 34.56 27.63 26.76 0.59 256.19 200 200 20 20 0.4 208.39 187.78 20 20.62 100 100 10 0.2 10 11.36 10 11.42 0.25 0 0 0 0 0 0 Q4'FY20 Q4'FY21 Q4'FY20 Q4"FY21 Q4'FY20 Q4'FY21 Q4'FY20 Q4'
Slide 53: Financial Highlights (Annual)
consolidated Rs. in crores 12M'FY21 FINANCIAL HIGHLIGHTS ^39% ^36% ^67% ^152% ^189% ^189% 1,250 1,250 150 100 100 2 1200.12 1,000 1,000 130.58 98.51 97.09 1069.54 100 75 75 1.5 750 862.55 750 2.16 784.55 78.00 50 50 1 500 500 50 25 39.11 0.5 250 250 25 33.58 0.75 0 0 0 0 0 0 FY20 FY21 FY20 Q4"FY21 F
Slide 54: Operating Ratios
consolidated Rs. in crores 12M'FY21 OPERATING RATIOS -9% ^5% ^16% ^168% ^74% ^108% 2 5 2.5 25 10 10 1.82 4.67 4.88 2 1.5 1.66 4 20 2.06 7.5 8.54% 7.5 8.38% 53.71 3 1.5 1.77 15 1 5 2 1 20.05 5 10 4.92% 0.5 2.5 4.03% 1 0.5 5 2.5 0 0 0 0 0 0 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 d
Slide 55: Balance Sheet Ratios
standalone Rs. in crores 12M'FY21 BALANCE SHEET RATIOS --- ^42% ^29% ^31% ^101% ^90% 100 400 0.5 100 25 15 89.96 89.96 0.4 607.73 75 300 0.43 20 316.16 75 21.1% 0.3 10 11.33 15 50 200 222.06 0.31 50 0.2 10 25 464.76 10.5% 5 100 0.1 25 5 5.96 0 0 0 0 0 0 FY20 FY21 FY20 FY21 FY20 FY21 FY20 FY21 FY20 F
Slide 56: Thank you
Thank you
Morepen Laboratories — Q4 FY2021 Earnings Presentation on 6ix